350 related articles for article (PubMed ID: 36125471)
1. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
Devauchelle-Pensec V; Carvajal-Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel BJ; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A
JAMA; 2022 Sep; 328(11):1053-1062. PubMed ID: 36125471
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.
Bonelli M; Radner H; Kerschbaumer A; Mrak D; Durechova M; Stieger J; Husic R; Mandl P; Smolen JS; Dejaco C; Aletaha D
Ann Rheum Dis; 2022 Jun; 81(6):838-844. PubMed ID: 35210264
[TBL] [Abstract][Full Text] [Related]
3. Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
Spiera RF; Unizony S; Warrington KJ; Sloane J; Giannelou A; Nivens MC; Akinlade B; Wong W; Bhore R; Lin Y; Buttgereit F; Devauchelle-Pensec V; Rubbert-Roth A; Yancopoulos GD; Marrache F; Patel N; Dasgupta B;
N Engl J Med; 2023 Oct; 389(14):1263-1272. PubMed ID: 37792612
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study.
Devauchelle-Pensec V; Berthelot JM; Cornec D; Renaudineau Y; Marhadour T; Jousse-Joulin S; Querellou S; Garrigues F; De Bandt M; Gouillou M; Saraux A
Ann Rheum Dis; 2016 Aug; 75(8):1506-10. PubMed ID: 26929219
[TBL] [Abstract][Full Text] [Related]
5. 1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial.
Bolhuis TE; Marsman DE; den Broeder AA; den Broeder N; van der Maas A
Lancet Rheumatol; 2023 Apr; 5(4):e208-e214. PubMed ID: 38251523
[TBL] [Abstract][Full Text] [Related]
6. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
[TBL] [Abstract][Full Text] [Related]
7. Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial.
Saraux A; Le Henaff C; Dernis E; Carvajal-Alegria G; Tison A; Quere B; Petit H; Felten R; Jousse-Joulin S; Guellec D; Marhadour T; Kervarrec P; Cornec D; Querellou S; Nowak E; Souki A; Devauchelle-Pensec V
Lancet Rheumatol; 2023 Dec; 5(12):e728-e735. PubMed ID: 38251563
[TBL] [Abstract][Full Text] [Related]
8. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial.
Salvarani C; Macchioni P; Manzini C; Paolazzi G; Trotta A; Manganelli P; Cimmino M; Gerli R; Catanoso MG; Boiardi L; Cantini F; Klersy C; Hunder GG
Ann Intern Med; 2007 May; 146(9):631-9. PubMed ID: 17470831
[TBL] [Abstract][Full Text] [Related]
9. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR; Buttgereit F; Bernasconi C; Álvaro-Gracia JM; Castro N; Dougados M; Gabay C; van Laar JM; Nebesky JM; Pethoe-Schramm A; Salvarani C; Donath MY; John MR;
Lancet; 2020 Jul; 396(10246):267-276. PubMed ID: 32711802
[TBL] [Abstract][Full Text] [Related]
10. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable.
Devauchelle-Pensec V; Saraux L; Berthelot JM; De Bandt M; Cornec D; Guellec D; Marhadour T; Jousse-Joulin S; Gouillou M; Saraux A
Rheumatology (Oxford); 2018 Apr; 57(4):666-670. PubMed ID: 29346621
[TBL] [Abstract][Full Text] [Related]
11. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial.
Caporali R; Cimmino MA; Ferraccioli G; Gerli R; Klersy C; Salvarani C; Montecucco C;
Ann Intern Med; 2004 Oct; 141(7):493-500. PubMed ID: 15466766
[TBL] [Abstract][Full Text] [Related]
12. Concordance and agreement between different activity scores in polymyalgia rheumatica.
D'Agostino J; Souki A; Lohse A; Carvajal Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel B; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A; Devauchelle-Pensec V
RMD Open; 2024 Mar; 10(1):. PubMed ID: 38490696
[TBL] [Abstract][Full Text] [Related]
13. Trial of Tocilizumab in Giant-Cell Arteritis.
Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schett G; Schulze-Koops H; Spiera R; Unizony SH; Collinson N
N Engl J Med; 2017 Jul; 377(4):317-328. PubMed ID: 28745999
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial.
Spiera R; Unizony SH; Bao M; Luder Y; Han J; Pavlov A; Stone JH
Semin Arthritis Rheum; 2021 Apr; 51(2):469-476. PubMed ID: 33784598
[TBL] [Abstract][Full Text] [Related]
15. Treatment of polymyalgia rheumatica: a systematic review.
Hernández-Rodríguez J; Cid MC; López-Soto A; Espigol-Frigolé G; Bosch X
Arch Intern Med; 2009 Nov; 169(20):1839-50. PubMed ID: 19901135
[TBL] [Abstract][Full Text] [Related]
16. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
17. Primary Care Vasculitis: Polymyalgia Rheumatica and Giant Cell Arteritis.
Pioro MH
Prim Care; 2018 Jun; 45(2):305-323. PubMed ID: 29759126
[TBL] [Abstract][Full Text] [Related]
18. PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial.
Marsman DE; Bolhuis TE; den Broeder N; den Broeder AA; van der Maas A
Trials; 2022 Apr; 23(1):318. PubMed ID: 35428320
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy.
Mori S; Koga Y
Clin Rheumatol; 2016 May; 35(5):1367-75. PubMed ID: 24803231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
